Cyclacel has contributed to many scientific advancements.
Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS). Cancer 2021; doi: 10.1002/cncr.33828.
Expansion of phase 1 study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations. Proc. Ann. Meeting AACR, 2019, Mar 29–Apr 3; Atlanta, GA, Abstract CT050.
Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood 2017, 130: Abstract 891.
Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. J Clin Oncol 34, 2016 (suppl; Abstract 2503).
Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors. Proceedings of the 104th Annual Meeting AACR; 2013, Apr 6-10; Washington, DC. Philadelphia, PA: AACR; 2013. Abstract LB-202.
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012, 13:1096-1104.
Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukaemia. J Clin Oncol 29: 2011 (suppl; Abstract 6587).
Understanding the pathways involved in the repair of CNDAC induced DNA damage. Proceedings of the 101st Annual Meeting AACR; 2010, Apr 17-21; Washington DC, Abstract 3502.
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010, 28:285-291.